-
Mashup Score: 2Hospital Consolidation and Physician Unionization | NEJM - 5 day(s) ago
Most physicians now face the experience of being employees of hospitals or other large organizations. Unionization is a natural consequence of consolidation and the corporatization of health care …
Source: www.nejm.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 2Hospital Consolidation and Physician Unionization | NEJM - 6 day(s) ago
Most physicians now face the experience of being employees of hospitals or other large organizations. Unionization is a natural consequence of consolidation and the corporatization of health care …
Source: www.nejm.orgCategories: General Medicine News, Hem/OncsTweet-
@VincentRK corporate medicine has led us away from providing quality healthcare, we are diverted to numerous have to’s that are not helpful We are losing our way and our culture Hospital Consolidation and Physician Unionization | New England Journal of Medicine https://t.co/y1Ai9hf1ZL
-
-
Mashup Score: 2Hospital Consolidation and Physician Unionization | NEJM - 10 day(s) ago
Most physicians now face the experience of being employees of hospitals or other large organizations. Unionization is a natural consequence of consolidation and the corporatization of health care …
Source: www.nejm.orgCategories: General Medicine News, Hem/OncsTweet-
@VincentRK corporate medicine has led us away from providing quality healthcare, we are diverted to numerous have to’s that are not helpful We are losing our way and our culture Hospital Consolidation and Physician Unionization | New England Journal of Medicine https://t.co/y1Ai9hf1ZL
-
-
Mashup Score: 2Hospital Consolidation and Physician Unionization | NEJM - 11 day(s) ago
Most physicians now face the experience of being employees of hospitals or other large organizations. Unionization is a natural consequence of consolidation and the corporatization of health care …
Source: www.nejm.orgCategories: General Medicine News, Hem/OncsTweet-
@VincentRK corporate medicine has led us away from providing quality healthcare, we are diverted to numerous have to’s that are not helpful We are losing our way and our culture Hospital Consolidation and Physician Unionization | New England Journal of Medicine https://t.co/y1Ai9hf1ZL
-
-
Mashup Score: 6
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned coprimary or secondary analyses are not yet available. Clinical trial updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. We present the final analysis of the phase III noninferiority, randomized ShortHER trial comparing 9 weeks versus 1 year of adjuvant trastuzumab with chemotherapy in patients with human epidermal growth factor receptor 2–positive (HER2+) early breast cancer (BC). Women with HER2+ BC were randomly assigned to anthracycline-taxane combinations plus 1-year trastuzumab (arm A, long) or 9-week trastuzumab (arm B, short). Here, we report the second coprimary end point overall survival (OS), updated disease-free survival (DFS), and outcomes according to hormone receptor status,
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet-
Nine-Week Versus One-Year Trastuzumab for Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: 10-Year Update of the ShortHER Phase III Randomized Trial | Journal of Clinical Oncology https://t.co/eJGNayymgn
-
-
Mashup Score: 0Hidden metastatic lung tumour diagnosed by AI - 1 month(s) ago
A 75-year-old woman who attended for a routine x-ray appointment was given the all-clear after the image was reported as having no atypical findings (figure). The investigation had been arranged as part of the follow-up package for the patient who, 3 years earlier, had an abdominoperineal resection for rectal and anal cancer. The rectal carcinoma was a moderately to well differentiated tubular adenocarcinoma, 25 mm × 20 mm, pT2N0M0 stage I; the anal carcinoma was a squamous cell carcinoma, 5 mm × 5 mm, pTisN0M0 stage 0.
Source: www.thelancet.comCategories: General Medicine News, Hem/OncsTweet-
Could anyone confirm if computer-aided detection with XR or CT is routinely being utilized as an adjunct to radiologist readings? Hidden metastatic lung tumour diagnosed by AI - The Lancet https://t.co/VfRWjV2Ecn
-
-
Mashup Score: 0SGO Statement: Carboplatin and Cisplatin Shortages | Society of Gynecologic Oncology - 1 year(s) ago
Currently, a U.S. shortage of carboplatin and cisplatin exists that will likely last several months and possibly longer. Platinum drug shortages were first reported to the U.S. Food and Drug Administration (FDA) on February 10, 2023. The recommendations below addressRead More ›
Source: Society of Gynecologic OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
@OncBrothers @ASCO try again with link! https://t.co/QRD7Kmd6mM
-
-
Mashup Score: 0
The majority of pancreatic cancers are diagnosed at an advanced stage, when surgical options are limited and treatment relies on systemic chemotherapy. In the NAPOLI-1 trial, liposomal irinotecan in combination with fluorouracil (nal-iri/5FU) was shown …
Source: PubMed Central (PMC)Categories: Hem/Oncs, Latest HeadlinesTweet-
@ILSONDavid @agrothey and the cost!!! based on this report liposomal irinotecan 100x more expensive than irinotecan. @BijoyTelivala #gi23 1 month 5FU/iri $123 vs 1 month naliri/5FU $12,000 https://t.co/rR7kQ34fmT
-
-
Mashup Score: 0
The majority of pancreatic cancers are diagnosed at an advanced stage, when surgical options are limited and treatment relies on systemic chemotherapy. In the NAPOLI-1 trial, liposomal irinotecan in combination with fluorouracil (nal-iri/5FU) was shown …
Source: PubMed Central (PMC)Categories: Hem/Oncs, Latest HeadlinesTweet-
@BijoyTelivala @MPishvaian You hit the nail on the head! monthly cost of Naliri 5FU $12,039 per month FOLFIRI $123, maybe price has changed? https://t.co/rR7kQ34fmT
-
-
Mashup Score: 0
In a zebrafish model of human cutaneous and acral melanomas, CRKL amplification causes tumours to favour a fin location, indicating that tumour location is determined by both the driver oncogenes and the pre-existing positional identity gene program.
Source: NatureCategories: Hem/Oncs, Latest HeadlinesTweet-
@tony_breu Great thread Thanks, Maybe it has something to do with the specific mutations in a particular cancer, and their relevance regarding location. On a related note why do cancers develop in certain locations Nature 604, 354–361 (2022). https://t.co/G3y7E6A4no
-
@VincentRK corporate medicine has led us away from providing quality healthcare, we are diverted to numerous have to’s that are not helpful We are losing our way and our culture Hospital Consolidation and Physician Unionization | New England Journal of Medicine https://t.co/y1Ai9hf1ZL